INFLUENCE OF BACTERIOTHERAPY ON NASAL AND TONSILLAR MICROBIOTA IN INFLUENZA PATIENTS by Sydorchuk, Aniuta et al.
 THE ADVANCED SCIENCE JOURNAL HEALTH SCIENCES 
 
 
86 DOI: 10.15550/ASJ.2016.01.086 
 
INFLUENCE OF BACTERIOTHERAPY ON NASAL 
AND TONSILLAR MICROBIOTA IN INFLUENZA 
PATIENTS 
 
Aniuta Sydorchuk, Vasyl Moskaliuk,  
Yurii Randiuk, Leonid Sydorchuk 
Bukovinian State Medical University, Ukraine 
sidorchuk@bsmu.edu.ua 
 
Received 14-JAN-2016; Accepted 23-FEB-2016; Online 01-MAR-2016 
 
Abstract: This paper deals with study of species composition and population level of nasal and 
tonsillar microbiota in adults. Contamination of mucous membranes with S.aureus, S.pyogenes, 
S.viridans, H. influenzae, K.pneumoniae, E. coli, S. pneumoniae, fungi of Candida genus in adults 
infected with influenza viruses had determined. It had been established in vitro the influence alike 
antagonistic activity of Bacillus subtilis and Bacillus licheniformis strains towards inhibition of bacterial 
growth of Staphylococcus aureus, Streptococcus pyogenes strains: after 24 hours for 24,15±0,17%, 
after 48 hours – to 44,65±0,22% and after 72 hours – to 58,94±0,23%. Permanent antagonistic 
activity had appeared onto S. pyogenes also in 24 hours, gradually increased and reached up to 
73,33±0,19% in 72 hours. It was observed the decreasing of population level of pathogenic and 
opportunistic organisms of tonsillar and nasal mucosae against the background of complete 
elimination of S. aureus, K. pneumonia, S. pyogenes, S.viridans, S. epidermidis, H. influenzae, S. 
pneumoniae, E. coli, fungi of Candida genus (p<0.05). 
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Introduction 
Influenza is ubiquitous, but complications are more common in the intertropical zone because of 
local climatic and socioeconomic conditions. According to the WHO, worldwide, the annual epidemics of 
the disease result in about 3 to 5 million cases of severe illness, and about 250.000 to 500.000 deaths.  
Viral influenza is a seasonal infection associated with significant morbidity and mortality. In the 
USA, more than 35,000 deaths and 200,000 hospitalizations due to influenza occur annually, and the 
number is increasing. Annual vaccination is the cornerstone of prevention, but some older patients 
may derive less benefit from immunization than otherwise fit individuals. If started promptly, antiviral 
medications may reduce complications of acute influenza, but increasing resistance to amantadine 
and perhaps neuraminidase inhibitors underscores the need for novel prevention and treatment 
strategies (Glezen, 2008). Pulmonary complications of influenza are most common and include 
primary influenza and secondary bacterial infection. Staphylococcus aureus, including methicillin-
resistant strains, is an important cause of secondary bacterial pneumonia with high mortality 
(Rothberg, 2008). 
In spite of a great quantity of modern medicines for a treatment of patients with influenza, there 
is still often development of bacterial complications. From one side it determined by dysfunction of 
systemic immunity, especially cellular section, and from another it realized due to activation of 
opportunistic microorganisms, which are present on the mucous membranes of nasal and tonsillar 
surfaces. By the Cochrane databases, staphylococci and streptococci are the most distributed 
pathogenic and conventionally pathogenic microbes persisted on tonsillar and nasal mucosae. Thus 
primary their role in development of purulent bacterial complications on the background of acute 
respiratory infections posted as a great (Joseph, Togawa and Shindo, 2013).  
Recent scientific interest increased in the field of microbiology as well as the place and role of 
probiotics in pharmacotherapy of infectious diseases. There are few experimental research dedicated 
to positive influence of bacillus contained bacterial preparations due to their antagonistic activity 
towards pathogenic strains (Shobharani, Padmaja and Halami, 2014). However, analysis of available 
literature data proved that current clinical study with experimental microbiologic part had conducted 
firstly in adults with seasonal influenza A and B in Ukraine and Eastern Europe. 
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It is predicted that Bifidobacterium and Bacillus strains may express antagonism versus 
staphylococcus and streptococcus, hence in fact it may use for prevention of secondary bacterial 
influenza complications. 
 
Method 
Current prospective study enrolled 107 patients aged 18-25 (average 21.7 years old) had 
conducted in Infectious Disease Department of Chernivtsi Municipal Clinical Hospital. All enrolled was 
infected with seasonal influenza viruses A and B. Gender allocation included 62 (56.9 %) females and 
45 (43.1 %) – males. Investigated persons were belonging to Caucasian race. All enrolled persons 
having the same high risk to get influenza virus because of student activity based on the 
epidemiologic data being upon same exposure during communication and overcrowding. One 
hundred and nine young patients with clinical features and laboratory findings (acute onset with 
hyperthermia more 38.5
0
C, headache, intoxication syndrome, etc., positive epidemiologic data) were 
investigated during October-December 2015 at the Dept. of Droplet Respiratory Infections in the 
Municipal Clinical Hospital, Chernivtsi (South Western region of Ukraine, Eastern Europe). 
Research material (smears from nasopharynx, tonsils) of case (influenza virus infected persons) 
and control groups – 30 healthy volunteers of same age and gender allocation, had delivered to 
Microbiological Clinical Laboratory of Municipal Clinical Hospital (Chernivtsi, Ukraine) with purpose to 
evaluate a species composition and population level of nasal and tonsillar microflora. Cultures of 
facultative anaerobic and aerobic bacteria had cultured in an incubator (37
0
C) for 24-48 hours. 
Obligate anaerobic bacteria had grown in the stationary anaerostat «CO2-Incubator» T-125" (Sweden, 
EU) during 5-7 days, rarely up to 14 days. Then received single-type colonies had studied for each 
genus of the microbes, from the colonies there had obtained pure cultures of obligate and facultative 
anaerobic and aerobic microorganisms. Pure culture identified by genus (species) by morphological, 
tinctorial, cultural and biochemical properties.  
Identification of isolated microorganisms was done by Bergey’s Manual of Systematic Bacteriology. 
Antagonistic activity studied by classical microbiologic experiment in vitro as simultaneous cultivation in 
selective nutrient media (yolk-salt agar, serum agar) of bacillus-contained probiotic and clinical strain of 
microbes from patients mucous membrane (S. aureus, S.pyogenes mostly).  
The 67 persons infected with influenza A & B had agreed to participate with further clinical part of 
the research. After detailed explanation of the methodic of bacillus-contained probiotic application, 
they signed up the “Patient consent form” and continued the multimodality treatment with drops of 
bacillus-contained probiotic (content of ampule with dry powder was diluted in 2 ml of isotonic solution, 
then applied 2 drops into nose, 2 drops into each tonsil surface, within 7 days) and orally intake 
capsules of Bifidobacterium-contained probiotic by scheme (1 capsule three times per day, 7 days).  
Mathematic, statistical analysis of the results was performed by the method of variation statistics 
with the definition of average value, average error, and probability of possible error by statistical 
Student’s t-test by means of Biostat® PC program (USA). 
 
Results 
All enrolled patients had admitted to Infectious Department of Municipal Clinical Hospital 
(Chernivtsi, Bukovina) with purpose of stationary treatment. Influenza caused by A/H3N2 and 
A/H2N2/ in investigated young patients characterized mostly by a moderate severity course. Influenza 
caused by B type virus had mild severity course.  
Examined patients complained on moderate headache, dry persistent cough, general weakness, 
louse of appetite, pain in chest (98,17±1,28), pain an eyeballs (96,33±1,80), myalgia (88,99±3,00) 
and arthralgia – in 76,15±4,08 cases. 
The diagnosis of influenza had proved by clinical data, epidemiologic anamnesis. The result of 
serological authentication proved: influenza A/N2N2 – in 46,78±4,78% cases, influenza A/N3N2 – in 
40,36±4,70% and B – at 6,42±2,34% patients at Bukovina (Western Ukraine) during the epidemic 
season 2014-2015 years.  
Authors defined several microorganisms persisted on nasal and tonsillar mucous membranes of 
infected patients with seasonal influenza: Staphylococcus aureus, Streptococcus pyogenes, 
Streptococcus epidermidis, Streptococcus viridans, Streptococcus pneumoniae, Enterobacter 
(Escherichia, Klebsiella pneumoniae), Haemophilusinfluenzae, Candida. The foregoing bacteria were 
detected (in 60,55±4,68 % patients) more often as monoculture, and also as associations which 
include two (in 35,78±4,59% cases) and three (in 2,75±1,46% patients) species of opportunistic 
microorganisms. Their population level as quantitative figure reached high critical level – more than 
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four lgCFU/ml that proved potential possibility of development of purulent secondary complications 
(bacterial lobar pneumonia, acute sinusitis, lacunar tonsillitis, etc.). 
Initially, the simultaneous 72 hours cultivation of Staphylococcus aureus and Streptococcus 
pyogenes clinical strains with the bacillus–contained probiotic had performed on selective medium (in 
vitro). Resulted this, Bacillus subtilis & Bacillus licheniformis as antagonistic active components of 
mentioned above bacterial preparation depressed the growth and reproduction of S. aureus clinical 
strain: after 24 hours for 24,15±0,17%, after 48 hours – to 44,65±0,22% and after 72 hours – to 
58,94±0,23% comparatively with cultivation without bacillus-contained probiotic. Permanent 
antagonistic activity had appeared onto S. pyogenes also in 24 hours, gradually increased and 
reached up to 73,33±0,19% growth inhibition in 72 hours.  
It was observed the decreasing of population level of pathogenic and opportunistic organisms of 
tonsillar and nasal mucosae against the background of complete elimination of S. aureus, K. 
pneumonia, S. pyogenes, S.viridans, S. epidermidis, H. influenzae, S. pneumoniae, E. coli, fungi of 
Candida genus (p<0.05).  
 
Discussion 
By current study, the quantitative and qualitative parameters of the microflora of tonsils and nose 
mucosa in patients infected with influenza viruses A/N2N2 and A/N3N2, B subtypes during the 
season from October to March, which is typically for eastern European countries and Ukraine 
particularly had defined; generally, the data matched with other researches. As Raid Yaqoub Yousef 
demonstrated (2014), staphylococcus aureus is the most commonly grown organism in the core of 
the tonsil and/or surface culture (65 patients out of 73) (89.05%); group A beta-hemolytic streptococci 
was isolated in 53.43%; Haemophilus influenza was isolated in 46.58% patients who need 
tonsillectomy because of recurrent chronic tonsillitis. It is well-known fact that viral respiratory 
infections including influenza viruses pathophysiological lead to different disorders of immune system; 
logically, that “did a favor” for persisting pathogenic or either conventionally pathogenic bacteria 
strains present over nasal and pharyngeal mucous membranes of human.  
Many studies investigating the effect of probiotics conclude that they confer their benefits on 
health by boosting the immune system (Ashraf and Shah, 2014). Kobayashi M. et al. (2011) 
introduced heat-killed Lactobacillus pentosus b240 into a mouse model infected with influenza virus 
A/H1N1. Although their study did not show that the probiotic affected the replication of the virus and 
cytokine production, it showed that the probiotic regulated gene expression in the influenza viruses 
found in the lung of the mouse. This result is important because it demonstrates that probiotics may 
disarm cold and flu viruses without necessarily killing them off. The task of destroying the viruses 
rests with immune cells such as leucocytes and NK cells. In addition, the results demonstrated that 
this inhibition of influenza virus occurred in the lungs. Moreover, antiviral effect of probiotics occurs in 
the respiratory tract, the very organ-system most affected by respiratory viruses. By T. Kawahara, T. 
Takahashi (2015), Bifidobacterium, one of the major components of intestinal microflora, shows anti-
influenza virus potential as a probiotic, partly through enhancement of innate immunity by modulation 
of the intestinal immune system. Bifidobacterium longum MM-2, a very safe bacterium in humans, 
was isolated from healthy humans and its protective effect against infection in a murine model shown. 
The results show that species composition of tonsillar and nasal microflora in patients infected 
with seasonal influenza viruses A/H3N2, A/H2N2 and B type defined as different compared with 
healthy volunteers. Authors revealed the contamination of mucous membranes with S.aureus, 
S.pyogenes, S.viridans, H. influenzae, K.pneumoniae, E. coli, S. pneumoniae, fungi of Candida 
genus. Moreovermentioned above pathogens in 60,55±4,68 % patients detected as monoculture, and 
bi-associations in 35,78±4,59% cases. Obviously, high population levelof coccihardly multiplies the 
risk for development of secondary bacterial complications. This research provides powerful evidence 
that antagonistic activity of Bacillus- and Bifidobacterium-contained probiotics towards S. aureus, S. 
pyogenescould inhibit them up to total elimination from nasal and tonsillar microbiota in vitro and in 
vivo. Multimodality treatment with drops of bacillus-contained probiotic (content of ampule with dry 
powder was diluted in 2 ml of isotonic solution, then applied 2 drops into nose, 2 drops into each 
tonsil surface, within 7 days) and orally intake capsules of Bifidobacterium-contained probiotic by 
scheme (1 capsule three times per day, 7 days). Second microbiological investigation of tonsillar and 
nasal microflora after probiotics application proved the elimination of S.aureus, S.pyogenes in mostly 
cases (p<0.05). The resultsdemonstratethe effectiveness of combination probiotic therapy confirmed 
firstly in vitro, thus further in clinics enrolled patients within 7 days in holiatry of influenza A & B in adults. 
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